Dextran nanobubbles were prepared with a dextran shell and a perfluoropentan core in which oxygen was stored. To increase the stability polyvinylpirrolidonewas also added to the formulation as stabilizing agent. Rhodamine B was used as fluorescent marker to obtain fluorescent nanobubbles. The nanobubble formulations showed sizes of about 500 nm, a negative surface charge and a good capacity of loading oxygen, no hemolytic activity or toxic effect on cell lines. The fluorescent labelled nanobubbles could be internalized in Vero cells. Oxygen-filled nanobubbles were able to release oxygen in different hypoxic solutions at different time after their preparation in in vitro experiments. The oxygen release kinetics could be enhanced after nanobubble insonation with ultrasound at 2.5 MHz. The oxygen-filled nanobubble formulations might be proposed for therapeutic applications in various diseases.

Preparation and characterization of dextran nanobubbles for oxygen delivery

CAVALLI, Roberta;BISAZZA, AGNESE;LEMBO, David;GUIOT, Caterina;TROTTA, Michele
2009-01-01

Abstract

Dextran nanobubbles were prepared with a dextran shell and a perfluoropentan core in which oxygen was stored. To increase the stability polyvinylpirrolidonewas also added to the formulation as stabilizing agent. Rhodamine B was used as fluorescent marker to obtain fluorescent nanobubbles. The nanobubble formulations showed sizes of about 500 nm, a negative surface charge and a good capacity of loading oxygen, no hemolytic activity or toxic effect on cell lines. The fluorescent labelled nanobubbles could be internalized in Vero cells. Oxygen-filled nanobubbles were able to release oxygen in different hypoxic solutions at different time after their preparation in in vitro experiments. The oxygen release kinetics could be enhanced after nanobubble insonation with ultrasound at 2.5 MHz. The oxygen-filled nanobubble formulations might be proposed for therapeutic applications in various diseases.
2009
381
160
165
Cavalli R; Bisazza A; Giustetto P; Civra A; Lembo D; Trotta G; Guiot C; Trotta M
File in questo prodotto:
File Dimensione Formato  
jpharm2_09_OA.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 668.88 kB
Formato Adobe PDF
668.88 kB Adobe PDF Visualizza/Apri
jpharm2_09.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 848.97 kB
Formato Adobe PDF
848.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/100028
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 106
  • ???jsp.display-item.citation.isi??? 100
social impact